A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-29 | estimated | When the study began enrolling |
| Primary completion | 2025-07-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-07 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ischemic Stroke
Interventions
- Drug: BIIB131
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart 1: Percentage of Participants with Arterial Revascularization
measured Up to 6 hours
Part 1: Percentage of Participants with Reperfusion of the Ischemic Field
measured Up to 6 hours
Part 2: Ordinal Modified Ranking Scale (mRS) Score Based on a 6-Point Ordinal Scale
measured Day 90
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed